Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Safety and Efficacy of Mavacamten for Treatment of Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Publisher



Rabiee Rad M1 ; Ghasempour Dabaghi G1 ; Habibi D2
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Isfahan University of Medical Science, Hezarjarib Ave, Isfahan, 81746-73461, Iran
  2. 2. Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Science, Isfahan, Iran

Source: Egyptian Heart Journal Published:2023


Abstract

Background: Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. Main body: A total number of 539 patients were enrolled in four randomized clinical trials. The mean age of patients was 57.9 years and was followed for 29.3 weeks. Pooled analysis showed a significant improvement in clinical response (Log OR = 0.65; p = 0.01) and the number of patients with a reduction of ≥ 1 NYHA function class (Log OR = 0.64, p = 0.00). It was found that mavacamten did not significantly affect the Kansas City Cardiomyopathy Questionnaire (KCCQ) (SMD = 0.43, p = 0.08), peak oxygen uptake (PVO2) (SMD = 0.24, p = 0.42), and ejection fraction (EF) (SMD = − 0.65, p = 0.13) as compared with placebo. However, KCCQ (SMD = 0.65, 95% CI 0.44–0.87) and PVO2 (SMD = 0.49, 95% CI 0.24–0.74) improvements were statically significant in the hypertrophic obstructive cardiomyopathy subgroup (HOCM), and a significant decrease in EF (SMD = -− 1.14, 95% CI − 1.86 to − 0.42) was found in the HOCM subgroup. No significant difference was observed in the incidence rate of serious adverse events between mavacamten and placebo group (Log OR = − 0.23, p = 0.56). Conclusions: Mavacamten proved to be effective and well-tolerated for the treatment of HCM. Mavacamten improved the signs and symptoms of HOCM and decreased EF in these patients without serious adverse events in the clinical trials. © 2023, The Author(s).
Experts (# of related papers)
Other Related Docs
35. How to Write a Systematic Review: A Narrative Review, International Journal of Preventive Medicine (2021)
37. Newborn Screening for Galactosaemia, Cochrane Database of Systematic Reviews (2017)
42. Newborn Screening for Galactosaemia, Cochrane Database of Systematic Reviews (2016)
44. Ultrasonographic Assessment of Carpal Tunnel Syndrome Severity: A Systematic Review and Meta-Analysis, American Journal of Physical Medicine and Rehabilitation (2019)